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1. Introduction  
According to the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 
million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 
64% of the deaths occurred in the economically developing world (Jemal et al., 2011).  
It is now 51 years since Macfarlane Burnet and Peter Medawar won the Nobel Prize in 
Physiology or Medicine for the discovery of acquired immunological tolerance, and Burnet’s 
‘hypothesis that called for experiment’ has driven an enormous amount of progress. A 
recent advance in anti-cancer therapies has been the use of cancer antigen to develop 
vaccines. However, immunization with cancer cell-based vaccines has not resulted in 
significant long-term therapeutic benefits. The search for human tumor antigens as potential 
targets for cancer immunotherapy has led to the discovery of several molecules expressed 
mainly or selectively on cancer cells.  
Vaccination is an effective medical procedure of clinical oncology setting based on the 
induction of a long-lasting immunologic memory characterized by mechanisms endowed 
with high destructive potential and specificity. In the last few decades, identification of 
tumor-associated antigens (TAA) has prompted the development of different strategies for 
antitumor vaccination, aimed at inducing specific recognition of TAA in order to elicit a 
persistent immune memory that may eliminate residual tumor cells and protect recipients 
from relapses. Current data from trials with cancer vaccine for patients with advanced 
cancer are however not uniform. Because enormous problems arise from the variability of 
protocols in the preparation of vaccine, such as dendritic cell-based or peptide vaccine, and 
the vaccination itself.  
Widely occurring, over-expressed TAAs have been detected in different types of tumors  
as well as in many normal tissues, and their over-expression in tumor cells can reach  
the threshold for T cell recognition, breaking the immunological tolerance and triggering  
an anticancer response. Many antigens have been identified and studied as potential targets 
for vaccine therapy, and several vaccine methods have been investigated to target them.  
The most well-studied and promising vaccines for the treatment of cancer can be subdivided 
into three main groups: antigen-specific vaccines, tumor cell vaccines, and dendritic  
cell vaccines.  
Active immunotherapy is aimed either at eliciting a specific host immune response against 
selected cancer antigens by employing cancer vaccines or at amplifying the existing 
antitumor immune response by administering nonspecific proinflammatory molecules or 
adjuvants. Dendritic cells (DCs) are the most potent antigen-presenting cells in vitro and in 
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vivo. DCs have a central function in the activation of specific effector T cells. On this basis, 
vaccination strategies with DC were regarded as a promising therapeutic approach even in 
advanced tumor diseases. DC have always been described as having two distinct functional 
stages: 1) immature, with high antigen uptake and processing ability, and poor T-cell 
stimulatory function; 2) mature, with high stimulatory function and poor antigen uptake 
and processing ability. DC internalize cancer antigens and process their proteins then 
display them as short peptides on the extracellular surface, in conjunction with major 
histocompatibility complex (MHC) class I and II molecules. DC then migrates into the 
corresponding lymph nodes, where it matures and present antigen to naïve T lymphocytes. 
Helper T cells (CD4+) recognize their cognate antigens (MHC class II molecules) located on 
DCs, whereas CD8+ cytotoxic T lymphocytes (CTLs) recognize affected foreign or cancer 
cells which display the complementary peptide-MHC class I molecule on their cell surfaces. 
Targeted cell death occurs by perforin/granzyme-induced apoptosis or FAS-L/Fas 
interaction. Activation of CD4+ T cells leads to the secretion of cytokines such as IFN-γ and 
IL-12, which in turn augment the stimulation of active CD8+ T cells. Cancer vaccine aimed at 
inducing specific recognition of TAA as well as eliciting persistent immune memory T 
lymphocytes. Programmed death-1 (PD-1) and anti-cytotoxic T lymphocyte-associated 
protein 4 (CTLA-4) are induced on T cells after a TCR signal, and result in cell cycle arrest 
and termination of T-cell activation. Blocking by either CTLA-4 or PD-1 monoclonal 
antibodies can sustain the activation and proliferation of tumor-specific T cells (Hirano et al., 
2005; Hodi et al., 2008). Although, to date, no autologous cellular immunotherapy has 
gained wide use in clinical practice, the first such therapy to show clinical efficacy in a phase 
3 study recently gained U.S. Food and Drug Administration (FDA) approval for the 
treatment of prostate cancer. Sipuleucel-T consists of autologous PBMCs loaded with 
recombinant human prostatic acid phosphatase (PAP) linked to granulocyte-macrophage 
colony stimulating factor (PAP-GM-CSF), which has proven to be effective in phase III 
clinical trials. DC based Vaccine are typically prepared by harvesting large numbers of 
autologous peripheral blood mononuclear cells (PBMCs) by leukapheresis, then culturing 
these cells and loading them with antigens ex vivo and injecting them back into the patient. 
Three general methods have been described concerning DC based vaccine: (1)differentiating 
DCs from non-proliferating monocyte precursors (so-called “monocyte-derived DCs”; 
(2)differentiating DCs from proliferating CD34+ hematopoietic progenitor cells; or 
(3)directly isolating DCs or mixed APCs from periphereal blood. Autologous DC can be 
loaded with a wide assortment of antigen types, including whole tumor cells or cell lysates, 
or TAA in the form of synthetic peptides, purified or recombinant proteins, RNA, plasmid 
DNA or non-replicating recombinant viral vectors (Mayordomo et al., 1995; Thurner et al., 
1999). Immunogenicity may be enhanced by using antigens combined or fused with other 
more immunogenic molecules, including xenogeneic proteins such as Keyhole Limped 
Hemocyanin (KLH) or IL-2, TNF-α, IFN-γ or Toll-like receptor agonist. Adapting single 
peptide for vaccine is not preferable, because after complete objective response to NY-ESO-1 
peptide vaccine, but later recurred with a NY-ESO-1–negative tumor, proving that single-
target immunization can result in immune escape tumor variants after initial response 
(Odunsi et al., 2007). A desirable alternative to vaccines are multiepitope or whole tumor 
antigen vaccines created using autologous tumor lysate or tumor-derived RNA, which may 
have universal applicability (Chianese-Bullock et al., 2008; Tsuda et al., 2007). 
However, the immune responses are often weak, and data on clinical efficacy are limited, as 
most of these have been small, single arm studies designed only to evaluate safety and 
immunogenicity. An enormous problem arises from the variability of protocols in the 
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preparation of DC and in the vaccination itself. A meta-analysis of 56 published peer-
reviewed immunotherapy trials of melanoma that used either molecular defined synthetic 
antigens or whole tumor antigen (4,375 patients) found that only 25.3% of patients 
vaccinated had objective clinical control (Chi & Dudek , 2011). 
A number of studies have found that development of tumor and an unfavorable prognosis 
for cancer patients were accompanied by accumulation of natural CD4+CD25+Foxp3+ T 
regulatory cells (Tregs) in peripheral blood, as well as of peripherally induced Tregs in the 
tumor itself (Wilczynski et al., 2008). Furthermore, depletion of Treg is a critical maneuver to 
enhance vaccine therapy. Different therapeutic immune strategies have been tested 
preclinically and are currently in evaluation in early phase I and II trials. DC based vaccine 
is usually given to peripheral site, whereas Natural Killer (NK)-T cell and LAK are either 
delivered systematically or into the tumor site. Results from these trials vary, but the overall 
increased survival and/or clinical efficient benefit obtained so far has been limited. In 
addition, MHC expression level vary cancer type and stage, it seems difficult to eradicate 
cancer just administrating vaccine. Because CTL induced by vaccine targets MHC expressed 
cancer cell, whereas NK cell attacks MHC non-expressed cancer cell. 
Only three randomized phase 3 clinical trials of DC/APC vaccines for the treatment of 
cancer have been published.  The first study compared subcutaneously administered 
cytokine-matured, Mo-DCs loaded with a mixture of MHC class II and II-restricted 
peptide antigens to conventional chemotherapy in patients with stage IV melanoma. 
Designed to compare clinical response rates as measured by tumor regression, the study 
showed no statistically significant difference in clinical outcomes between the two 
treatments. With the FDA-approval of sipuleucel-T, cancer vaccine has become an 
accepted approach for the treatment of cancer. However, it is not known if the use of 
dendritic cells or mixed APCs for the active immunotherapy of cancer has an advantage 
over more conventional vaccine approaches, which are simpler and much less expensive. 
We usually propose WT1, MUC1, CEA, CA125, HER-2/neu, and PSA as cancer antigens 
for DC based therapy according to the patient’s primary lesion and elevated tumor 
marker (Sugiyama, 2005; Mukherjee et al., 2000; Nair et al., 1999; Larbcurrentet et al., 
2007). It has been reported that WT1 and MUC1 is antigens with high immunogenicity 
and their-targeted immunotherapy have confirmed its safety and clinical efficacy, 
although there is few description concerning cancer vaccine adapting WT1 and MUC1 
simultaneously to cancer antigen (Ramanathan et al., 2005). Dr Okamoto and his 
colleagues have already reported that OK-432 generates mature DCs via Toll-like receptor 
4 signaling and that OK-432-activated DCs stimulates CD8+ T cells to induce antigen-
specific CTLs (Ahmed et al., 2004, Itoh et al., 2003; Nakahara et al., 2003; Okamoto et al., 
2003, 2004, 2006; Oshikawa et al., 2006). In this analysis efficacy of cancer vaccine, 
different potential means of DC based vaccination in experimental settings and 
preliminary data from clinical trial have been examined. 
2. Material and method  
2.1 Patients, treatment and sampling 
This retrospective study was carried out in accordance with the standards of our 
Institutional Committee for the Protection of Human Subjects. Eligible patients must be 
those who have failed standard treatment. Informed written consent according to the 
Declaration of Helsinki was obtained from all patients before giving this therapy, and the 
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collection of the samples was approved by the Institutional Review Board. From 2007 to 
2010, 127 patients with advanced cancer refractory to standard treatment were treated with 
DC-based immunotherapy (DC vaccine alone or DC vaccine plus NK-T cell therapy) at 
Kudan Clinic Immune Cell Therapy Center.  
Initial patient evaluations included a medical history and physical examination; 
measurement of performance status, hemoglobin, WBC count, platelet count, blood urea 
nitrogen, creatinine, alkaline phosphatase, lactate dehydrogenase, AST, ALT, bilirubin, and 
tumor marker levels; HbA1c; Computed Tomography (CT) scans or Magnetic Resonance 
Imaging (MRI) of whole body. Patients with evidence of operable tumor were ineligible. To 
be eligible, patients were required to have an ECOG performance status of less than 3.  
Eligible Adequate hematologic, hepatic, and renal function, within the following 
parameters: WBC count of 2,500/μl or greater; platelet count of 100,000/μl or greater; 
hemoglobin value of 10 g/dl or greater; blood urea nitrogen value less than 50 mg/dl; 
serum bilirubin level less than 5.0 mg/dl; AST level lower than 500 IU. 
Autologous DCs (1 x 107 cells) were administered intradermally at 14-day intervals. 
Tolerable 1 to 5 KE of OK-432 (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan), a 
streptococcal immunological adjuvant, was administered together with DC vaccine. NK-T 
cells were simultaneously injected in as many patients at 14-day intervals.  
The clinical response was evaluated on the basis of the Response Evaluation Criteria in Solid 
Tumors (RECIST) Ver1.0 as follows: complete remission (CR), partial remission (PR), stable 
disease (SD), and progressive disease (PD). Adverse events were evaluated by grading the 
toxicity according to the National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4.0. 
2.2 Preparation of DCs and NK-T cells 
PBMCs-rich fraction was obtained from leukapheresis (400 ml x 13 cycles) using COM.TEC 
(Fresenius Kabi, Homburg, Germany). The PBMCs were isolated from the heparinized 
leukapheresis products by Ficoll-Hypaque gradient density centrifugation (Böyum, 1967). 
These PBMCs were placed into 100 mm plastic tissue-culture plates (Becton Dickinson 
Labware, Franklin Lakes, NJ) in AIM-V medium (Gibco, Gaithersburg, Md). After 30 min of 
incubation at 37°C, nonadherent cells were removed, and the adherent cells were cultured in 
AIM-V containing granulocyte-macrophage colony stimulating factor (GM-CSF, 500 ng/ml; 
Primmune Inc., Kobe, Japan), and IL-4 (250 ng/ml; R&D Systems Inc., Minneapolis, MN) to 
generate immature DCs (Okamoto et al., 2004). The population of the adherent cells 
remaining in the wells was composed of 95.6 ± 3.3% CD14+. After 5 days of the cultivation, 
the immature DCs were stimulated to be matured with OK-432 (10 μg/ml) and 
Prostaglandin E2 (50 ng/ml; Daiichi Fine Chemical Co. LTD., Toyama, Japan) for 24 hrs. It 
has been reported that Prostaglandin E2 acquires the ability to migrate to the lymph node to 
DCs (Sato et al., 2003). Peptides (20 μg/ml) for WT1, Her2 and CEA were pulsed into the 
DCs at 24 hrs after the treatment with OK-432 and with Prostaglandin E2, while MUC1 long 
peptide (30 mer) (20 μg /ml), CA125 protein (500 U/ml) and autologous tumor lysates (50 
μg/ml) were added into the DC culture media at the same time as adding OK-432 and 
Prostaglandin E2, then incubated for 24 hrs (Kontani et al., 2002; Cannon et al., 2004). To 
prepare the autologous tumor lysates, tumor masses were obtained by surgical resection 
exclusion, and were then homogenized. Aliquots of the isolated tumor cells were then lysed 
by putting them through 10 freeze (in liquid nitrogen) and thaw (in a 37 oC water bath) 
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cycles. The lysed cells were centrifuged at 14000 g for 5 min, and the supernatants were 
passed through a 0.22 μm filter (Millipore Corporation, Bedford, MA). The protein contents 
of the resultant cell-free lysates were determined using DC protein assay kits (Bio-Rad 
Laboratories, Hercules Aliquots (500 μg/tube) were then cryopreserved at -135 oC until use 
(Nagayama et al., 2003). Surface molecules expressed in the DCs were determined using 
flow cytometry. The cells defined as the mature DCs were CD14-, HLA-DR+, HLA-ABC+, 
CD80+, CD83+, CD86+, CD40+, and CCR7+.  
For preparation of NK-T cells, PBMCs were cultured with an immobilized monoclonal anti-
CD3 antibody (5 μg/mL OKT3; Jansen Pharmaceutical K.K., Tokyo, Japan) in the presence 
of recombinant human IL-2 (175 U/mL; CHIRON, Benelux B.V., Amsterdam, Netherlands) 
and autologous plasma for 14 days. Fresh NK-T cells were prepared every injection as 
described above; it was composed of more than 85% of aǃ-T cells and about 10% of 
NK/NKT cells. 
2.3 Vaccine quality control 
All vaccines were subjected to a quality-control evaluation, which were assessed the total 
number of live dendritic cell, monocyte-derived dendritic cell characteristics, and 
percentage of viable cells. For a vaccine to be deemed “adequate,” there must have been 4 x 
107 viable dendritic cells. 
2.4 FACS analysis 
The frozen cells were allowed to thaw in a 37 oC water bath quickly and retrieved from the 
cryopreservation tubes by rinsing with 0.02% albumin containing Cell Wash™ (eBioscience, 
San Jose, CA) (FACS buffer). The FACS analysis was performed for cell surface antigen 
staining. FITC-labeled anti-human CD14, CD40, CD80, HLA-A, B, C, PE-labeled anti-human 
CD11c, CD83, CD197 (CCR7+), HLA-DR and FACS Calibur Flowcytometer were purchased 
from BD Bioscience, and used for the FACS analysis.  
3. Results 
3.1 Clinical outcome of patients with DC-based vaccine 
Computed tomography scans or MRI was done before and at the end of dendritic cell 
therapy. Of 127 patients who received DC vaccine, complete responses (n = 4; 3.1%), partial 
responses (n = 26; 20.5%), or stable disease were observed in 34 (26.8%) (Table 1.). 
Although the study was not designed or powered to detect differences between other 
vaccine treatment groups, it was of interest to compare the response and survival of patients 
treated with other vaccines.  
Most patients received NK-T therapy in combination with the DC vaccination as to induce 
Th (helper T cell) 1-dominant state for improved CTL response and to attack non-MHC 
expressed carcinoma cells. The NK-T cells generated according to the methods described in 
the “Materials and Methods” section secrete IFN-Ǆ and IL-2, and induce helper T cell (Th) 1-
dominant state in the cytokine balance of the patients (Chong et al., 1994).  
3.2 Adverse events 
Therapy was well-tolerated during the treatment and 3 months after last administration. 
None of the patients experienced adverse events of grade 3 or higher during the treatment 
period, grade 1 to 2 fevers, grade 1 injected-site reaction consisting of erythema, induration 
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Table 1. Clinical Outcome of Patients treated with DC based vaccine  
and tenderness, lasting 24 to 48 hours after injection in 8 patients and resulted in no dose 
modifications or delays. No signs or symptoms of auto-immune phenomena (eg, arthritis, 
colitis, inflammation of skin) were observed either during or after therapy.  
4. Discussion 
Interest in antitumor vaccination arose around 1900 when a series of microbial vaccines by 
Dr William B. Coley proved to be effective. Boon T and others provided an unambiguous 
definition of TAA, an important finding the genetic and molecular identification of a large 
series of TAA (Coulie, 1997; Robbins & Kawakami, 1996).  
In many cases, TAA are peptides presented by class I and class II glycoproteins of the MHC. 
A similar picture is emerging from phase I studies on vaccination of cancer patients. 
However, clinical responses to the immunotherapy with DC vaccination have only been 
observed in a minority of patients with solid cancer. Initiation of immune responses requires 
that professional APC deliver a first signal to T-lymphocytes through the binding of the T-
cell receptor by the peptide enclosed in the HLA molecule, that is responsible for the 
specificity of the immune response, and a second or co-stimulatory signal that is not 
antigen-specific but it is required for T-cell activation mainly through CD80 (B7-1) and CD86 
(B7-2) binding to CD28 receptor, or the CD40:CD40L pathway (Janeway & Bottomly, 1994). 
Moreover, the capacity of DC to activate NK cells by ligation of the CD40 molecule with its 
counter-receptor has recently been demonstrated (Cayeux et al., 1999; Kitamura et al., 1999). 
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Therefore, given the complex network of regulatory signals by professional APC and naïve 
and memory T lymphocytes occurring in antigen-specific immune responses, it is not 
surprising that tumor cells may fail to induce efficient immune reactions even when a well 
known TAA is present. From among the professional APC, DC are the most potent 
stimulators of T cell responses and play a crucial role in the initiation of primary immune 
responses (Banchereau & Steinman, 1998). DC have always been described as having two 
distinct functional stages: 1) immature, with high antigen uptake and processing ability, and 
poor T-cell stimulatory function; 2) mature, with high stimulatory function and poor antigen 
uptake and processing ability. Despite several immunotherapeutic approaches having 
been tested for colon cancer patients, only one study has reported clinical results in a 
prospective randomized study (Vermorken et al., 1999). Experimental data and clinical 
evidence suggest that antitumor vaccines will be a new form of tumor treatment that will 
be able to be adopted for the management of defined stages of carcinoma, in sequential 
association with conventional treatments (Sadanaga et al., 2001). Prediction of when the 
efficacy of antitumor vaccination will be assessed and will become a routine procedure is 
beyond a simple scientific evaluation. While pre-clinical research has identified several 
possible targets and strategies for tumor vaccination, the clinical scenario is far more 
complex. The main cell populations taking part in immunoregulation of tumor growth are 
presented in Fig. 1. 
 
 
 
 
Fig. 1. The main anti-tumor immune cell responses by DC and NK/NKT cell 
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Most peptide-based vaccines have considered HLA class I restricted peptides only, whereas 
there is increasing evidence that tumor-specific CD4+ T-cells may be important in inducing 
an effective antitumor immunity. The addition of peptides that bind class II HLA 
glycoproteins to peptide vaccines could lead to an amplification of the immune response as 
well as to better clinical effect. The possibility of effectively monitoring the immune 
response induced acquires critical importance since it may provide a much earlier surrogate 
end-point, predictive of the clinical outcome. An ideal TAA is a protein that is essential  
for sustaining the malignant phenotype, and that is not stripped or down modulated by  
the immune reaction. TAAs were sorted by their anti-tumor potential such as therapeutic 
function, immunogenicity, oncogenicity, specificity, expression level and % positive  
cells, and cancer stem cell expression. Among the 75 peptides evaluated by Dr Martin  
A. Cheever, WT1 was the 1st and MUC1 was the 2nd anti-tumor effect (Cheever et al.,  
2009). WT1 was originally identified as tumor suppressor gene for Wilm’s tumor. WT1  
over-expression has been detected in different malignant cell types including 
gastroenterological carcinoma, gynecological carcinoma, lung carcinoma, prostate, breast 
carcinoma and hematological malignancy. MUC1 is expressed at high levels over the entire 
surface of diverse types of carcinoma cells such as gastroenterological carcinoma, 
gynecological carcinoma, NSCLC, prostate and breast carcinoma. MUC1 transmembrane 
receptor has revealed a function for this subunit as an oncoprotein that is targeted to the 
nucleus and regulates gene expression. MUC1-C accelerates the malignant potential by 
regulating gene transcription, blocking stress-induced apoptosis and necrosis, and 
attenuating activation of death receptor pathways.  
When compared with conventional cancer management, vaccination is a soft, non-invasive 
treatment free from particular distress and iatrogenic side effects. Antitumor vaccines can be 
expected to have a considerable social impact, but a few large clinical trials enrolling the 
appropriate patients are now necessary to assess their efficacy. In conclusion, even if cancer 
vaccines are an old dream, only recently has their design become a rational enterprise 
(Ehrlich, 1909). There are now many ways of constructing vaccines able to elicit a strong 
protective immunity. This progress is offering ground for optimism. 
Here, we demonstrate that WT1 and/or MUC1 pulsed DC vaccination is feasible, safe, and 
sufficiently powerful to induce objective clinical and immune responses even in patients 
with significant tumor burden. Several studies of ex vivo, custom-manufactured cancer 
vaccines using patient-specific idiotype, idiotype-pulsed dendritic cells, and tumor lysate–
pulsed dendritic cells have also demonstrated objective clinical responses and these prior 
results prompted our pursuit of the practicable in situ approach. 
This approach-by its nature-must be studied in patients with clinically evident disease, in 
contrast to the described randomized studies (Flowers, 2007; Freedman et al., 2009). As 
compared with other comparably practical vaccines current vaccination has the potential 
advantage of using more potential TAA encompassing each individuals’ relevant tumor 
antigens. In addition, several recent immune-response studies showing that vaccine-induced T 
cells peak at day 14 and decline sharply thereafter, have prompted earlier immune-response 
measurements in an ongoing follow-up study (Deng et al., 2004; Kim et al., 2007; Treanor et al., 
2006). There is little or no controversy that patients with Treg-inducing tumors had poorer 
clinical outcomes after vaccination. This biomarker could be either a specific predictor of 
response to in situ vaccination or a general prognosticator of poor outcomes regardless of 
therapy. Interestingly, patients with highly Treg-infiltrated tumors have shown favorable 
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clinical outcomes after standard therapy (Carreras et al., 2006; Tzankov et al., 2008). If Treg 
induction predicts good response to standard therapy, but a poor response to the in situ 
vaccine, then it would be a powerful clinical tool for selecting appropriate patients for 
vaccination. This interesting finding is still preliminary and is being evaluated prospectively in 
an ongoing follow study (ClinicalTrials.gov-ID: NCT00880581). That the vaccine preparation 
in current study was optimal was evident from quality-control assessments, because in the 
study presented here, all vaccines didn’t fail to meet quality-control specifications. As 
prognosis of most advanced carcinoma who failed standard therapy is poor, establishment of 
effective therapeutic modality for advanced carcinoma is an urgent issue.  
Immunotherapy would be implied as one of the important therapeutic modalities against 
advanced carcinoma and even adjuvant settings because WT1 and MUC1, highly 
immunogenic target molecules for adaptive anti-tumor immune response, were frequently 
expressed in most carcinoma tissue (Cheever et al., 2009; Oka et al., 2006). DC-based 
vaccination has several advantageous aspects for induction and activation of tumor antigen-
specific CTLs compared with CTL-epitope peptide-based vaccination (Melief & van der 
Burg, 2008). Patients with advanced carcinoma who failed standard therapy and met eligible 
criteria enrolled in current study. Response rate was 23.6%, whereas control ratio was 50.4%. 
It is a significant tumor control ratio compared with other historical modalities much less no 
severe adverse event. Is the strongest result from this trial the apparent increase in control 
ratio?  It would be important to understand the mechanisms of immune system underlying 
the significant increase in cancer control ratio. These results indicate that WT1 and/or 
MUC1 pulsed DC-based vaccination can elicit significant clinical benefit even for the 
advanced cancer patients refractory to the standard therapies. Although there was a trend 
toward treatment being superior to standard treatment only, there was no statistical 
consideration. However, the study demonstrated that successful active specific 
immunotherapy with WT1 and/or MUC1 pulsed DC-based vaccine may be dependent on 
the quality of the vaccine as well as TAAs. These encouraging preliminary results suggest 
that WT1 and/or MUC1 pulsed DC-based vaccination warrants further study as a novel 
therapy for patients with advanced carcinoma. The combination of cytotoxic therapy and 
intratumoral immune stimulation has been studied preclinically for a variety of common 
tumor types and might also be directly translated to the clinic (Meng et al., 2005; Najar et al., 
2008; VanOosten & Griffith, 2007). This trial clearly supports the idea that to be 
immunologically effective, control of the vaccine preparation and the quality assurance that 
the vaccine meets specifications are of the highest priority and must be considerations in 
any future tumor cell vaccine study. A key element in these novel strategies is the 
identification of suitable patients, the selection being based on detailed immunological and 
molecular characterization. The most promising finding that emerges from this study is that 
WT1 and/or MUC1 pulsed DC-based vaccine together with NK-T cell therapy elicit strong 
anti-tumor response. Progress in the formulation of cancer vaccines will be brought by a 
more precise knowledge of the requirements for the potent generation of efficient CTL 
induction and NK cell expansion as well as discovering potent TAA, together with the 
current ability to closely monitor molecular immune response prediction markers in, will 
likely provide powerful, individualized vaccines in the near future.  
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